Liquidia (LQDA) shares fell 10% following United Therapeutics’ (UTHR) surprise unveiling of TreSMI, a next-gen inhaled treprostinil aimed at reducing cough, despite no disclosed clinical data and plans to file later this year, Needham tells investors in a research note. The reaction appears overdone, as Yutrepia’s preliminary Q4 sales are already known and the key near-term catalyst remains the pending ‘327 patent litigation decision, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Maintaining Buy on Liquidia: Overreaction to TreSMI News and Attractive Risk-Reward Ahead of ’327 Patent Ruling
- Liquidia Technologies call volume above normal and directionally bullish
- Liquidia price target raised to $55 from $45 at Jefferies
- Liquidia: Robust Yutrepia Launch Trajectory and Market Leadership Prospects Justify Buy Rating Despite Patent Overhang
- Liquidia rises 18.2%